 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
Sertraline hydrochloride is a new naphthylamino compound that specifically blocks neuronal reuptake of serotonin. It is currently available in the United Kingdom and under review in the US. Sertraline follows first-order kinetics, with a plasma elimination half-life of 24-26 hours. It is highly bound to plasma proteins and has a large volume of distribution. Multicenter studies conducted by the manufacturer have shown sertraline to be efficacious in the treatment of depression and obsessive-compulsive disorder. The daily dose will range from 50 to 200 mg/d for the treatment of depression. The adverse-effect profile differs greatly from the tricyclic antidepressants, but is similar to that of fluoxetine. The most prominent adverse effects are gastrointestinal (nausea, diarrhea/loose stools, dyspepsia).
This article has been cited by other articles:
|
|
 |
|
  M. H. Pollack, M. W. Otto, J. J. Worthington, G. G. Manfro, and R. Wolkow Sertraline in the Treatment of Panic Disorder: A Flexible-Dose Multicenter Trial Arch Gen Psychiatry, November 1, 1998; 55(11): 1010 - 1016. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
